Theriva Biologics (NYSEAMERICAN:TOVX) Trading 0.7% Higher – Here’s What Happened

Shares of Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) shot up 0.7% during mid-day trading on Monday . The company traded as high as $0.2572 and last traded at $0.2529. 1,084,006 shares changed hands during trading, a decline of 93% from the average daily volume of 16,082,195 shares. The stock had previously closed at $0.2511.

Analysts Set New Price Targets

Separately, Maxim Group raised shares of Theriva Biologics from a “hold” rating to a “buy” rating and set a $1.00 price objective for the company in a research note on Tuesday, March 31st. One investment analyst has rated the stock with a Buy rating, According to MarketBeat.com, Theriva Biologics currently has an average rating of “Buy” and an average target price of $1.00.

Theriva Biologics Stock Up 0.7%

The firm has a 50-day moving average of $0.30 and a two-hundred day moving average of $0.24. The stock has a market capitalization of $8.53 million, a price-to-earnings ratio of -0.01 and a beta of 1.11. The company has a quick ratio of 1.63, a current ratio of 1.63 and a debt-to-equity ratio of 0.11.

Theriva Biologics (NYSEAMERICAN:TOVX) last announced its quarterly earnings data on Tuesday, May 5th. The company reported ($0.05) EPS for the quarter. The business had revenue of $0.30 million during the quarter.

Institutional Trading of Theriva Biologics

A hedge fund recently bought a new stake in Theriva Biologics stock. Two Sigma Investments LP purchased a new position in shares of Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 61,837 shares of the company’s stock, valued at approximately $25,000. Two Sigma Investments LP owned 0.64% of Theriva Biologics as of its most recent filing with the Securities and Exchange Commission (SEC). 6.17% of the stock is currently owned by hedge funds and other institutional investors.

Theriva Biologics Company Profile

Theriva Biologics, Inc, a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company’s lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma; and a Phase 1 clinical study for the treatment of solid tumors.